$SION News

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

Sionna's SION-719 Failure Changes Everything (Rating Downgrade)

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Guggenheim Downgrades Sionna Therapeutics to Neutral

Wedbush Downgrades Sionna Therapeutics to Neutral, Lowers Price Target to $5

Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

Sionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis - Slideshow

Sionna Therapeutics Announces Topline Data From Two Nucleotide Binding Domain 1 Stabilizer Programs; Precision CF Trial Did Not Meet Its Key Activity Endpoint; Phase 1 trial of SION-451 Achieved Safety, Tolerability And Pharmacokinetic Objectives

Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60

Sionna Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Citizens Reiterates Market Outperform on Sionna Therapeutics, Maintains $63 Price Target